Spaceflight radiation carcinogenesis Spaceflight radiation carcinogenesis Astronauts are exposed to approximately 50-2,000 millisieverts (mSv) while on six-month-duration missions to the International Space Station (ISS), the Moon and beyond. The risk of cancer caused by ionizing radiation is well documented at radiation doses beginning at 50 mSv and above. Related radiological effect studies have shown that survivors of the atomic bomb explosions in Hiroshima and Nagasaki, nuclear reactor workers and patients who have undergone therapeutic radiation treatments have received low-linear energy transfer (LET) radiation (x-rays and gamma rays) doses in the same 50-2000 mSv range. While in space, astronauts are exposed to radiation which
Radiation-induced lumbar plexopathy limiting the mean dose to < 45 Gy. One approach to reduced levels, the plexus' mapping with other organs at risk, was clinically evaluated during the 2010s. Clinical evidence of the cause-and-effect of prevention and the management of radiation induced polyneuropathy is limited. In 2011 the National Radiation Oncology Registry (NROR) was announced by the Radiation Oncology Institute (ROI). ROI and Massachusetts General Hospital would collect efficacy and side effect information (like radiation induced neuropathy) from people who had undergone radiotherapy. In 2013 the American Society for Radiation Oncology joined the effort. Experimental approaches of RILP treatment include: Radiation-induced lumbar